NDT Pharmaceuticals (NDTP) Stock Statistics & Valuation Metrics
Total Valuation
NDT Pharmaceuticals has a market cap or net worth of $7.75M. The enterprise value is $80.00T.
- Market Cap
- $7.75M
- Enterprise Value
- $80.00T
Share Statistics
NDT Pharmaceuticals has 197,204,350 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 197,204,350
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
NDT Pharmaceuticals’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.00%.
- Return on Equity (ROE)
- 0.00
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 0.00%
- Return on Capital Employed (ROCE)
- 0.00
- Revenue Per Employee
- ―
- Profits Per Employee
- ―
- Employee Count
- 0
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of NDT Pharmaceuticals is -7.71. NDT Pharmaceuticals’s PEG ratio is 0.03.
- PE Ratio
- -7.71
- PS Ratio
- 27.83
- PB Ratio
- 0.20
- Price to FCF
- -16.49
- Price to Operating Cash Flow
- -16.51
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, NDT Pharmaceuticals had revenue of 0 and earned -16.69K in profits. Earnings per share was -0.00.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -16.69K
- Pretax Income
- -16.69K
- Net Income
- -16.69K
- EBITDA
- -16.69K
- Earnings Per Share (EPS)
- -0.00
Cash Flow
In the last 12 months, operating cash flow was -470.01K and capital expenditures 7, giving a free cash flow of -470.00K billion.
- Operating Cash Flow
- -470.01K
- Free Cash Flow
- -470.00K
- Free Cash Flow per Share
- -0.00
Dividends & Yields
NDT Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.06%
- Earnings Yield
- -13.15%
Stock Price Statistics
- Beta
- 1.43
- 52-Week Price Change
- -96.13%
- 50-Day Moving Average
- 0.32
- 200-Day Moving Average
- 0.56
- Relative Strength Index (RSI)
- 28.49
- Average Volume (3m)
- 48.33K
Financial Position
NDT Pharmaceuticals as a current ratio of 0.00, with Debt / Equity ratio of 0.00%
- Current Ratio
- 0.00
- Quick Ratio
- 0.00
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.00
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, NDT Pharmaceuticals has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
NDT Pharmaceuticals EV to EBITDA ratio is -13.25, with an EV/FCF ratio of -17.81.
- EV to Sales
- 30.06
- EV to EBITDA
- -13.25
- EV to Free Cash Flow
- -17.81
- EV to Operating Cash Flow
- -17.81
Balance Sheet
NDT Pharmaceuticals has $80.85K in cash and marketable securities with $701.00K in debt, giving a net cash position of -$620.15K billion.
- Cash & Marketable Securities
- $80.85K
- Total Debt
- $701.00K
- Net Cash
- -$620.15K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.12
Margins
Gross margin is -145.05%, with operating margin of -365.55%, and net profit margin of -366.41%.
- Gross Margin
- -145.05%
- Operating Margin
- -365.55%
- Pretax Margin
- -366.41%
- Net Profit Margin
- -366.41%
- EBITDA Margin
- -226.88%
- EBIT Margin
- -365.55%
Analyst Forecast
The average price target for NDT Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -5100.00%
